ReviewCurrent opinion in immunology2011
The immunomodulatory properties of the CD5 lymphocyte receptor in health and disease.
Review in Current opinion in immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 92 citations in OpenAlex.
- iDCF: Interpretable deconvolution of cell fractions via biologically-informed deep learning using scRNA-seq data.PLoS computational biology · 2026Article
- Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed/refractory CD5Cell reports. Medicine · 2026Article
- The role of lymphocytic CD5 in the effects of ethanol on mesolimbic circuitry and ethanol consumption behavior.Brain, behavior, and immunity · 2026Article
- Convergence of mRNA technology and chimeric antigen receptor therapy: targeted technology optimizing targeted therapy.Journal of translational medicine · 2025Review
- The multiple functions of CD5 in diseases related to immune disorders.Annals of medicine · 2025Review
- Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- CD5 Expression in CTCL and Its Implications for Anti-CD5 CAR T-Cell Therapy.International journal of molecular sciences · 2025Article
- Global and Sex-Stratified Genome-Wide Association Study of Long COVID Based on Patient-Driven Symptom Recall.International journal of molecular sciences · 2025Article
- Cerebrospinal fluid protein profiling of inflammatory and neurobiological markers in Lyme neuroborreliosis.Scientific reports · 2025Article
- Article
- Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience.Thoracic cancer · 2024Article
- Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy.Theranostics · 2024Review
- Proteome analysis of CD5-positive diffuse large B cell lymphoma FFPE tissue reveals downregulation of DDX3X, DNAJB1, and B cell receptor signaling pathway proteins including BTK and Immunoglobulins.Clinical proteomics · 2023Article
- Immunity status and expression of molecular markers (ICAM-1, CD5, CD25, CD95) on lymphocytes of patients with recurrent anterior uveitis complicated by macular edema.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Uniting Disciplines to Develop Therapeutics: Targeted mRNA Lipid Nanoparticles Reprogram the Immune SystemDNA and cell biology · 2022Article
- The perception and response of T cells to a changing environment are based on the law of initial value.Science signaling · 2022Review
- A Meta-Analysis of the Safety and Efficacy of Maintenance Therapies for Antineutrophil Cytoplasmic Antibody Small-Vessel Vasculitis.Kidney international reports · 2022Article
- Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Review
- CAR T cells produced in vivo to treat cardiac injury.Science (New York, N.Y.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
CD5 is a scavenger-like receptor expressed in association with the antigen-specific receptors on T and B-1a lymphocytes. Recent studies reveal a broader biology for CD5 that includes its role as regulator of cell death and as a receptor for pathogen-associated molecular patterns, in addition to its previously described function as an inhibitory receptor. These findings shed new light into the mechanistic role of CD5 in leukemias and effector cells to exogenous (infectious) or endogenous (autoimmune, tumoral) antigens. The newly identified properties make this receptor a potential candidate to be targeted for therapeutic intervention as well as immune modulation. This review describes the current knowledge on the function of CD5 as an immunomodulatory receptor both in health and in disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.